Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Tenaya Therapeutics Inc. Common Stock
TNYA | US
0.69
USD-0.04
-5.73%
TNYA | US
Loading StockChartView...
About Tenaya Therapeutics Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
08/06/2026
Close
0.69
Open
0.72
High
0.73
Low
0.68
Tenaya Therapeutics Inc. a biotechnology company discovers develops and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration gene therapy and precision medicine platforms. The company is developing TN-201 a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy; TN-301 a small molecule for heart failure with preserved ejection fraction; and TN-401 a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy. It also develops an adeno-associated virus-based gene therapy designed to deliver the dwarf open reading frame gene in the heart for dilated cardiomyopathy; and reprogramming program for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco California.
View LessTNYA | US
Risk
68.7
Sharpe
0.20
Luna's Score
42/100
Recommendation
Sell
Luna says (TNYA | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
79.0%1 month
68.7%3 months
87.0%6 months
119.6%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.27
Debt to equity
0.12
Debt to assets
0.10
Ent. to EBITDA
-0.67
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-118.31M
MarketCap
70.11M
MarketCap(USD)
70.11M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-74.54
Short ratio
12.39
Short perc.
9.23
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.27
Range1M
0.47
Range3M
0.53
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.86
Price X volume
2.86M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.67 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.27 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 86.99 | 72.80 | Par |
| Debt to Equity | 0.12 | -1.23 | Expensive |
| Debt to Assets | 0.10 | 0.25 | Cheaper |
| Market Cap | 70.11M | 3.66B | Emerging |
